Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2008 Jun;9(6):591-604.

New combination therapies with cell-cycle agents.

Author information

1
University of Colorado Denver, School of Pharmacy, Department of Pharmaceutical Sciences, East 4200 9th Street, Box C238, Denver, CO 80262, USA.

Abstract

Cancer cells have deregulated cell-cycle progression with overexpression of positive regulators and inhibition of negative regulators, giving them unlimited replication potential. Therefore, development of agents targeting the deregulated cell cycle has been considered as an ideal strategy for cancer therapy. Cell-cycle-based agents have been categorized as cyclin-dependent kinase inhibitors, Cdc25 inhibitors, checkpoint inhibitors and mitotic inhibitors. These drugs have demonstrated preclinical efficacy, but their efficacy in the clinic has been modest and has been hampered by various side effects. Alternatively, their combination with chemotherapeutic drugs has been studied in different preclinical and clinical settings. Initial reports from these combination studies have been encouraging and suggest that combined drugs may be useful in lowering cancer burden.

PMID:
18516759
PMCID:
PMC2440501
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center